Immunohistochemical expression of GATA3 in urothelial carcinoma of urinary bladder
DOI:
https://doi.org/10.15218/zjms.2024.36Keywords:
Urothelial carcinoma, GATA3, ImmunohistochemistryAbstract
Background and objective: GATA3, an emerging immunohistochemical marker, is a zinc finger transcription factor that is expressed in normal urothelial epithelium and its corresponding neoplasms, and it has been recognized as a reliable urothelial related immunohistochemical marker. This study aimed to detect the frequency of GATA3 expression in urothelial carcinoma of urinary bladder and determine its association with some clinicopathologic parameters.
Methods: Seventy-nine formalin fixed paraffin embedded blocks of urothelial carcinoma cases were randomly selected from a private laboratory in Erbil city during October 2019 to October 2021. In this study, GATA3, a Rabbit monoclonal antibody was applied on urothelial carcinoma cases and its expression was assessed.
Results: GATA3 was expressed in 94.9% of the study cases. It was expressed in all non-invasive and low-grade urothelial carcinoma cases and 97.1% of papillary urothelial carcinoma cases, while it down-expressed in high-grade, invasive and non-papillary urothelial carcinoma cases. A significant association was noted between GATA3 expression and tumor pattern (P = 0.034), while no significant association was noted between GATA3 expression and other clinicopathologic parameters like age, gender, tumor grade, lympho-vascular invasion and tumor stage.
Conclusion: GATA3 is a useful diagnostic immunohistochemical marker for urothelial carcinoma, as this marker was expressed in 94.9% of urothelial carcinoma cases with a significant association with tumor pattern. Further studies are required to evaluate GATA3 expression in association with urothelial cancer progression and metastasis.
Metrics
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018; 68(6):394–424. https://doi.org/10.3322/caac.21492
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021; 71(3):209–49. https://doi.org/10.3322/caac.21660
Hussain AM, Lafta RK. Cancer Trends in Iraq 2000–2016. Oman Med J 2021; 36(1):e219. https://doi.org/10.5001%2Fomj.2021.18
Khoshnaw N, Mohammed HA, Abdullah DA. Patterns of cancer in Kurdistan-results of eight years cancer registration in Sulaymaniyah Province-Kurdistan-Iraq. Asian Pac J Cancer Prev 2016; 16(18):8525–31. https://doi.org/10.7314/APJCP.2015.16.18.8525
Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci 2020; 8(1):15. https://doi.org/10.3390/medsci8010015
McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol 2010; 28(4):429–40. https://pubmed.ncbi.nlm.nih.gov/20610280/
Wu G, Wang F, Li K, Li S, Zhao C, Fan C, et al. Significance of TP53 mutation in bladder cancer disease progression and drug selection. Peer J 2019; 7:e8261. https://doi.org/10.7717/peerj.8261
Roperch J-P, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, et al. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer 2016; 16(1):1–9. https://doi.org/10.1186/s12885-016-2748-5
Miettinen M, Cue PAM, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA 3–a multispecific but potentially useful marker in surgical pathology–a systematic analysis of 2500 epithelial and non-epithelial tumors. Am J Surg Pathol 2014; 38(1):13. https://doi.org/10.1097%2FPAS.0b013e3182a0218f
Asch-Kendrick R, Cimino-Mathews A. The role of GATA3 in breast carcinomas: a review. Hum Pathol 2016; 48:37–47. https://doi.org/10.1016/j.humpath.2015.09.035
Liu H, Shi J, Wilkerson ML, Lin F. Immunohistochemical Evaluation of GATA3 Expression in Tumors and Normal Tissues A Useful Immunomarker for Breast and Urothelial Carcinomas. Am J Clin Pathol 2012; 138(1):57–64. https://doi.org/10.1309/AJCP5UAFMSA9ZQBZ
Wang C, Yang S, Jin L, Dai G, Yao Q, Xiang H, et al. Biological and clinical significance of GATA3 detected from TCGA database and FFPE sample in bladder cancer patients. Onco Targets Ther 2020; 13:945. https://doi.org/10.2147/OTT.S237099
Hosoya T, Maillard I, Engel JD. From the cradle to the grave: activities of GATA‐3 throughout T‐cell development and differentiation. Immunol Rev 2010; 238(1):110–25. https://doi.org/10.1111/j.1600-065X.2010.00954.x
Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007; 31(5):673–80. https://doi.org/10.1097/01.pas.0000213438.01278.5f
Li Y, Ishiguro H, Kawahara T, Miyamoto Y, Izumi K, Miyamoto H. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res 2014; 4(5):461. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163611/?report=reader#
Miyamoto H, Izumi K, Yao JL, Li Y, Yang Q, McMahon LA, et al. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol 2012; 43(11):2033–40. https://doi.org/10.1016/j.humpath.2012.02.011
Kamel NA, Abdelzaher E, Elgebaly O, Ibrahim SA. Reduced expression of GATA3 predicts progression in non–muscle invasive urothelial carcinoma of the urinary bladder. J Histotechnol 2020; 43(1):21–8. https://doi.org/10.1080/01478885.2019.1667126
Agarwal H, Babu S, Rana C, Kumar M, Singhai A, Shankhwar SN, et al. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma. Indian J Pathol Microbiol 2019; 62(2):244. https://doi.org/10.4103/ijpm.ijpm_228_18
Naik M, Rao BV, Fonseca D, Murthy SS, Giridhar A, Sharma R, et al. GATA-3 expression in all grades and different variants of primary and metastatic urothelial carcinoma. Indian J Surg Oncol 2021; 12(1):72–8. https://doi.org/10.1007/s13193-019-01026-0.
Abdullah W, Kerbel H, Husseini R. Applying gata3 in differentiating urothelial carcinoma from prostatic adenocarcinoma: An immunohistochemical study. Asian J Pharm Clin Res 2018; 11(12):292–5. https://doi.org/10.22159/ajpcr.2018.v11i12.28232.
Chang A, Amin A, Gabrielson E, Illei P, Roden RB, Sharma R, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol 2012; 36(10):1472. https://doi.org/10.1097%2FPAS.0b013e318260cde7
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours. Eur Urol 2016; 70(1):106–19. https://doi.org/10.1016/j.eururo.2016.02.028.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67(2):93–9. https://doi.org/10.3322/caac.21388
Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol 2014; 45(7):1466–72. https://doi.org/10.1016/j.humpath.2014.02.023
Hoang LL, Tacha D, Bremer RE, Haas TS, Cheng L. Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma. Appl Immunohistochem Mol Morphol 2015; 23(10):711–6. https://doi.org/10.1097/PAI.0000000000000143.
Leivo MZ, Elson PJ, Tacha DE, Delahunt B, Hansel DE. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology 2016; 48(6):543–9. https://doi.org/10.1016/j.pathol.2016.05.008
Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7–positive carcinomas. Am J Clin Pathol 2014; 142(1):64–71. https://doi.org/10.1309/AJCP8H2VBDSCIOBF.
Bahria-Sediki IB, Yousfi N, Paul C, Chebil M, Cherif M, Zermani R, et al. Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. J Trans Med 2016; 14(1):1–11. https://doi.org/10.1186/s12967-016-0891-z
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Shadan Abdulkhaliq Jaf, Jalal Ali Jalal (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
